Please try another search
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company’s lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Name | Age | Since | Title |
---|---|---|---|
Kathleen Sereda Glaub | 70 | 2018 | Independent Director |
Mads Hald Andersen | - | - | Founder & Scientific Advisor |
Inge Marie Svane | - | - | Founder & Clinical Advisor |
Christian E. Elling | 54 | 2015 | Independent Director |
David V. Smith | 64 | 2022 | Independent Director |
Alexander Maximiliaan Marie Eggermont | - | - | Sr. Clinical Advisor & Member of the Scientific Advisory Board |
Kapil Dhingra | 65 | - | Strategic Advisory Board Member |
Heidi Hunter | 66 | 2023 | Independent Director |
Helen Louise Collins | 61 | 2023 | Independent Director |
K. Peter Hirth | 72 | 2016 | Independent Chairman |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review